2014


To access this material please log in or register

Register Authorize
2014/№5

Myths and reality of antithrombotic therapy in atrial fibrillation

Sulimov V. A., Napalkov D. A., Sokolova A. A.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: antithrombotic therapy, treatment, atrial fibrillation


DOI: 10.18087/rhj.2014.5.2005

The article provides most common statements related with atrial fibrillation (AF) and considers whether they are myths or reality.
  1. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82 (8A): 2N-9N.
  2. Verdecchia P, Reboldi G, Gattobigio R et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003 Feb;41 (2):218–23.
  3. Hornig CR, Brainin M, Mast H. Cardioembolic stroke: results from three current stroke data banks. Neuroepidemiology. 1994;13 (6):318–23.
  4. Bogousslavsky J, Regli F, Uské A, Maeder P. Early spontaneous hematoma in cerebral infarct: is primary cerebral hemorrhage overdiagnosed? Neurology. 1991 Jun;41 (6):837–40.
  5. Timsit SG, Sacco RL, Mohr JP et al. Brain infarction severity differs according to cardiac or arterial embolic source. Neurology. 1993 Apr;43 (4):728–33.
  6. Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol. 1986;43 (1);71–84.
  7. Arboix A, García-Eroles L, Oliveres M et al. Clinical predictors of early embolic recurrence in presumed cardioembolic stroke. Cerebrovasc Dis. 1998 Nov-Dec;8 (6):345–53.
  8. Hohnloser SH, Pajitnev D, Pogue J et al, for the ACTIVE W Investigators. Incidence of Stroke in Paroxysmal Versus Sustained Atrial Fibrillation in Patients Taking Oral Anticoagulation or Combined Antiplatelet Therapy. An ACTIVE W Substudy. J Am Coll Cardiol. 2007;50 (22):2156–2161.
  9. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation. 1991 Aug;84 (2):527–39.
  10. Healey JS, Hart RG, Pogue J et al. Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke. 2008;39 (5):1482–1486.
  11. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146 (12):857–867.
  12. Lip GY, Lowe GD. ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation. BMJ. 1996 Jan 6;312 (7022):45–9.
  13. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33 (21):2719–47.
  14. Сулимов В. А., Голицын С. П., Панченко Е. П. и др. Диагностика и лечение фибрилляции предсердий 2012 г. Рекомендации РКО, ВНОА и АССХ. Доступно на: http://scardio.ru / content / Guidelines / FP_rkj_13.pdf
  15. Connolly SJ, Eikelboom J, Joyner C et al, for the AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364 (9):806–817.
Sulimov V. A., Napalkov D. A., Sokolova A. A. Myths and reality of antithrombotic therapy in atrial fibrillation. Russian Heart Journal. 2014;79 (5):329–333

To access this material please log in or register

Register Authorize
Ru En